



lomab-B SIERRA trial results accepted for oral presentation at the European Hematology Association 2023 Congress

Stockholm, May 15 , 2023 – Immedica's partner Actinium Pharmaceuticals, Inc. has announced that an abstract on the lomab-B SIERRA trial results has been accepted for an oral presentation at the upcoming European Hematology Association 2023 Congress (EHA) which will be held in Frankfurt, Germany, June 8-11, 2023.

The abstract includes data from Actinium's controlled phase 3 study, SIERRA , comparing the efficacy of lomab-B based conditioning, a first-in-class targeted radiotherapy, versus physician's choice of conventional care in patients ≥ 55 years of age with relapsed/refractory acute myeloid leukemia (AML). This latest acceptance of the SIERRA trial results at EHA, a major medical conference, is helping spread awareness about the potential of lomab-B in facilitating allogeneic hematopoietic stem cell transplantations (HSCT) for patients with relapsed/refractory AML.

In April 2022 Immedica entered into a license and supply agreement with Actinium Pharmaceuticals, Inc. for lomab-B in Europe, the Middle East and North Africa.

Details of the EHA presentation are as follows:

Presentation Title: SIERRA trial results with a targeted radiotherapy, lomab-B, a myeloablative conditioning with reduced intensity tolerability yields high CR, long term survival in HSCT ineligible active r/r AML

Session Type/Title: Oral / SCT Clinical

Date and Time: June 10, 11:30am – 12:45pm CEST

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Actinium's clinical pipeline is led by targeted radiotherapies that are being applied to targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a bone marrow transplant (HSCT), gene therapy or adoptive cell therapy, such as CAR-T, to enable engraftment of these transplanted cells with minimal toxicities. www.actiniumpharma.com

About Immedica Pharma

Immedica is pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory and medical affairs as well as market access. Serving patients in more than 50 countries, Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need.

Immedica's therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 90 people across Europe and the Middle East.

For more information visit www.immedica.com

Immedica contact:

Linda Holmström
Head of Communication
linda.holmstrom@immedica.com
+ 46 708 73 40 95

Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm